Internal Medicine, Hematology & Oncology · East Brunswick, NJ
NPI
1093703969
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
629 Cranbury Rd Fl 2
East Brunswick, NJ, 08816
Phone (732) 390-7750
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.1M
128,329 services
Medicare patients, 2024
702
Average age 75
Drug cost, 2024
$3.6M
1,466 prescriptions
Company payments, 2025
$400
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Phillip D Reid was code J1439 (injection, ferric carboxymaltose, 1 mg), 33,750 times for 32 patients. In total Phillip D Reid billed 128,329 services in 144 codes, and Medicare paid $2.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-05-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 33,750 | 32 | $0.87 | $29K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 15,300 | 14 | $2.30 | $35K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 3,760 | 15 | $35.13 | $132K |
| J0897 Injection, denosumab, 1 mg | Office | 3,300 | 20 | $20.68 | $68K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 2,772 | 13 | $20.80 | $58K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,282 | 38 | $0.09 | $116 |
| 36415 Venipuncture Blood Collection | Office | 895 | 357 | $8.63 | $7,724 |
| 85027 Blood Count | Office | 786 | 223 | $6.32 | $4,971 |
| 99214 Office E&M - Established | Office | 740 | 343 | $115.39 | $85K |
| 96372 Injection Administration | Office | 526 | 129 | $12.83 | $6,747 |
| 85025 Blood Count | Office | 486 | 214 | $7.59 | $3,691 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 465 | 14 | $0.23 | $106 |
| 99213 Office E&M - Established | Office | 338 | 200 | $78.83 | $27K |
| 96367 Intravenous Infusion, Hydration | Office | 305 | 61 | $27.17 | $8,287 |
| 99232 Hospital E&M - Subsequent | Facility | 286 | 127 | $71.74 | $21K |
By year: 2022 $1.6M for 117,425 services; 2023 $1.9M for 129,913 services; 2024 $2.1M for 128,329 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 895 | 357 | $8.63 | $7,724 |
| 85027 Blood Count | 786 | 223 | $6.32 | $4,971 |
| 85025 Blood Count | 486 | 214 | $7.59 | $3,691 |
Medicare prescription drug claims, 2024
In 2024, the drug Phillip D Reid prescribed most often to Medicare patients was Xarelto (Rivaroxaban), with 148 prescriptions and refills. In total Phillip D Reid wrote 1,466 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | 148 | 236 | 24 | $127K |
| Anastrozole Generic | 112 | 291 | 35 | $2,506 |
| Hydroxyurea Generic | 80 | 179 | 21 | $2,288 |
| Aranesp Darbepoetin Alfa In Polysorbat | 76 | 76 | 19 | $229K |
| Eliquis Apixaban | 61 | 127 | 19 | $71K |
| Procrit Epoetin Alfa | 53 | 53 | Under 11 | $103K |
| Letrozole Generic | 52 | 118 | 13 | $1,613 |
| Prednisone Generic | 49 | 83 | 22 | $279 |
| Calquence Acalabrutinib Maleate | 44 | 44 | Under 11 | $451K |
| Oxycodone Hcl Generic | 43 | 43 | 14 | $1,044 |
| Neulasta Pegfilgrastim | 39 | 39 | Under 11 | $340K |
| Lupron Depot Leuprolide Acetate | 26 | 79 | 13 | $143K |
| Pomalyst Pomalidomide | 26 | 26 | Under 11 | $589K |
| Acyclovir Generic | 26 | 65 | Under 11 | $569 |
| Gabapentin Generic | 22 | 28 | Under 11 | $267 |
Brand drugs: 661 claims; generic drugs: 805 claims; opioid claims: 105.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Phillip D Reid $400 ($400 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $52.22.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 3 | $52.22 |
| Astellas Pharma US Inc 4503.T | 2 | $35.25 |
| Aveo Pharmaceuticals, Inc. | 1 | $27.59 |
| Myriad Genetic Laboratories, Inc. MYGN | 1 | $22.63 |
| BeOne Medicines USA, Inc. ONC | 1 | $22.35 |
| Celgene Corporation BMY | 1 | $21.93 |
| Eisai Inc. 4523.T | 1 | $21.22 |
| GlaxoSmithKline, LLC. GSK | 1 | $19.83 |
| Incyte Corporation INCY | 1 | $19.53 |
| Pfizer Inc. PFE | 1 | $19.49 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.